Viking Systems: Implementing a Public Start-Up Model
A year ago, Viking Systems Inc. reinvented itself based on the belief that it has found a way to take advantage of the public model to acquire small medical device companies and provide incentives to their entrepreneurial founders to work towards the greater good of an integrated company.
Viking will use combinations of stock, cash, and royalties tied to the future performance of products to acquire companies, products or services for the surgical suite that have strong intellectual property and revenues in the $500,000 to $10 million range. The idea is to take advantage of the medical device industry's fragmentation, both in terms of the large number of one-product companies that exist, and the requirement, in Viking's new target market-minimally invasive surgery--for numerous parts and pieces found within different types of companies. Its first acquisition was the visualization business of Vista Medical Technologies.
A year ago, Viking Systems Inc.
reinvented itself based on the belief that it has found a way to
take advantage of the public model to acquire small medical device
companies and provide incentives to their entrepreneurial founders
to work towards the greater good of an integrated company.
The firm had originally gone public in 2000 in a business that had nothing to do with health care; it...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
The KINCISE 2 Surgical Automated System aims to “reduce the physical burden on surgeons compared to manual impaction in primary and revision hip and revision knee replacement procedures,” said J&J MedTech.
J&J's EMEA head of digital solutions, Julia Fishman, talks about the major hurdles in scaling digital innovation, tips for clinical adoption and what’s up next on J&J’s innovation road map. Robot-assisted surgery pioneer Ivo Broeders gives his perspective on the difficulties in clinical adoption.
Quest reaffirmed its full-year guidance despite macroeconomic concerns and tariff uncertainty. Revenues are expected between $10.7bn and $10.85bn. Adjusted earnings per share (EPS) is estimated in the $9.55 to $9.80 range for the full year, with EPS between $8.62 and $8.87.
SAGA Diagnostics has launched its breast cancer residual and recurrence detection test – Pathlight – in the US. The test’s ultrahigh sensitivity and specificity is rare to see in oncology, the company claimed.
In this week's Digital Health Roundup, MedTech Insight's Shubham Singh explores how Ketryx's launch of validated AI agents could reshape compliance automation in medtech. Marion Webb highlights news from BCI makers Synchron, Axoft and Subsense. Elizabeth Orr discusses AI advances at the FDA.
Guardant Health’s methylation-based blood test – Shield MCD – showed a specificity of 98.6% and sensitivity of 75% across eight cancer types in its clinical validation data presented at ASCO.
DeepLook Medical recently announced the commercial rollout of DL Precise, an AI-powered imaging platform that enhances breast cancer screening, at major healthcare institutions across the US.
